Microscopic Solutions Lead to Great Advancements in Lung Cancer Treatment
The human body is incredibly complex; even the smallest malfunctions can cause a plethora of problems, especially at the molecular level. Cells, despite their tiny size, are incredibly intricate and know on their own whether or not to continue multiplying. This information is communicated to the cells through RAS proteins, which are found throughout the entire body. These proteins function almost like a switch that depends on how other proteins interact with it.
When GTP (a specific type of protein) binds to the RAS protein, the cells grow, and the opposite happens when the RAS protein binds to GDP. However, sometimes the genetic code for the RAS protein gets disrupted and dismisses the incoming signals. This can lead to the formation of tumors. Currently, this particular genetic mutation is responsible for around 30% of all cancers. Doctors and scientists have struggled for many decades to figure out a way to switch off this mutated protein to no avail, until now.
A study conducted at the University of Texas MD Anderson Cancer Center, led by Dr. David Hong, sought to investigate the effectiveness of a treatment called daraxonrasib, also known as Rasonque, on non-small cell lung cancer. They attempted to see if this new drug could prevent uncontrollable cell growth through the inhibition of the RAS protein. This newly-developed therapy pill works by latching onto cyclophilin A, a protein that transports other proteins throughout the body. There, the daraxonrasib will act as a “glue,” so when cyclophilin A naturally attaches itself to the RAS protein, it gets stuck. This clamp-like structure stops the protein from causing the body cells to multiply uncontrollably because the active site is blocked. This serves as a source of hope for individuals who have undergone multiple rounds of different types of cancer treatment but found that it was not effective enough.
The multicenter study referenced above included 136 patients whose cases were monitored starting in June of 2022 and ending in July 2025. The participants in the study were patients who had tried different cancer treatments but unfortunately could not find a substantial shrinkage or end in cancer cell growth. This experimental drug was given to the participants every day over the course of 21-day cycles. Different dosages were administered depending on the patients’ prior medical history and personal circumstances.
The trial found that 31% of patients had a 30% or greater shrinkage in non-small cell lung cancer. This is a massive achievement, especially when compared to other treatments currently available. While the treatment was successful to a certain degree, it unfortunately does not mean that the individuals were cured; rather, there was a significant decrease in the tumor’s mass, which was enough to say that daraxonrasib was effective.
Additionally, 99% of the participants experienced adverse side effects from the new treatment. These included nausea, rashes, vomiting and more. Out of all the participants, 54% experienced symptoms that were severe enough to prevent the person from taking care of themselves independently. Four participants passed away during the duration of the study. However, negative side effects are unfortunately typical of cancer treatments, and it was not unexpected.
The findings of this study were presented at the European Lung Congress in 2025, which prompted the start of the next phase of the trial. While as of now, daraxonrasib cannot be called a cure, it gives patients who have exhausted all options another chance of survival. This study also changed the scientific consensus on mutated RAS genes. Even though daraxonrasib is not infallible, it can serve as encouragement to future doctors and scientists of the world to look for unique and uncharted solutions.
Photo Caption: Medical professional examining chest x-ray
Photo Credit: Pexels
